GlassScriptPhysician profile
Tammy Kay Easterly
NPI 1649768805
$5,520.68
in general payments reported to CMS, 2019-2025
54 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2022: $760 · 2023: $1,321 · 2024: $1,924 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,374 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,374.37 |
| Education | $286.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.79 | 2023-2025 | |
| Janssen Biotech, INC. | $308.94 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Aveo Pharmaceuticals, INC. | $295.41 | 2022-2025 | Fotivda |
| Novartis Pharmaceuticals Corporation | $290.66 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $287.01 | 2023-2025 | Lynparza, Calquence, Imfinzi |
| Seagen INC. | $284.16 | 2021-2023 | Tukysa, Tivdak, Padcev |
| Daiichi Sankyo INC. | $271.01 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Regeneron Healthcare Solutions, INC. | $242.27 | 2023-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $201.44 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $201.40 | 2022-2025 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $200.92 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $190.73 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $132.94 | 2022-2025 | Reblozyl, Opdivo, Pomalyst |
| Genmab U.S., INC. | $125.00 | 2023 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $120.37 | 2023-2025 | Iclusig, Ninlaro |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $118.93 | 2022-2025 | |
| Kite Pharma, INC. | $116.34 | 2024 | |
| Astellas Pharma US INC | $105.92 | 2023-2025 | Padcev, Xtandi, Vyloy |
| Servier Pharmaceuticals LLC | $103.11 | 2024 | |
| Tersera Therapeutics LLC | $91.86 | 2023-2025 | Zoladex, Xermelo |
| Gilead Sciences, INC. | $81.94 | 2022-2024 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $80.25 | 2023-2025 | |
| Exelixis INC. | $72.60 | 2024 | Cabometyx |
| Adc Therapeutics America, INC. | $70.63 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $69.87 | 2023-2025 | Xpovio |
| Incyte Corporation | $69.20 | 2022-2025 | Monjuvi, Pemazyre |
| Dendreon Pharmaceuticals LLC | $67.87 | 2024 | Provenge |
| Genentech USA, INC. | $64.54 | 2023-2025 | Phesgo, Venclexta, Tecentriq |
| Puma Biotechnology, INC. | $62.14 | 2022-2024 | |
| Pfizer INC. | $58.71 | 2024-2025 | |
| Beigene USA, INC. | $58.38 | 2023-2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $57.29 | 2023-2024 | Tavalisse, Rezlidhia |
| Alexion Pharmaceuticals, INC. | $55.78 | 2022-2025 | Ultomiris |
| Blueprint Medicines Corporation | $54.81 | 2024-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $54.72 | 2023-2024 | |
| Taiho Oncology, INC. | $49.92 | 2023-2024 | |
| Genzyme Corporation | $41.71 | 2025 | |
| Pharmaessentia USA Corporation | $40.85 | 2023-2024 | Besremi |
| Array Biopharma INC | $40.17 | 2022-2023 | Braftovi, Paxlovid, Mektovi |
| Sumitomo Pharma America, INC. | $36.73 | 2024-2025 | Orgovyx |
| Verastem, INC. | $31.06 | 2025 | Avmapki Fakzynja Co-Pack |
| Deciphera Pharmaceuticals INC. | $26.90 | 2024 | Qinlock |
| Sun Pharmaceutical Industries INC. | $23.25 | 2024 | |
| Verity Pharmaceuticals INC. | $22.96 | 2024 | Trelstar |
| Novocure INC. | $21.86 | 2025 | Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $21.02 | 2023 | Monjuvi |
| Sobi, INC | $19.74 | 2024 | |
| Stemline Therapeutics INC. | $19.70 | 2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $19.50 | 2024 | Cosela |
| Geron Corporation | $18.85 | 2025 | Rytelo |
| Fennec Pharmaceuticals, INC. | $16.94 | 2025 | Fyarro |
| Amgen INC. | $15.86 | 2023 | Lumakras |
| Cti Biopharma Corp. | $15.36 | 2022 | |
| Mirati Therapeutics, INC. | $14.36 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Easterly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.